RxDoctor Payments Data

Brooke Lorenzen

Family · Council Bluffs, IANPI 1700456357

Payments from drug & device makers

$2,740in general payments, 2019–2025

Across 147 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$346
  • Novartis$314
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$248
  • Pfizer$204
  • Medtronic$190
  • Scpharmaceuticals Inc.$183
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,740 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$10,400
Medicare patients
106
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$18,084
XareltoRivaroxaban16$9,970
Torsemide38$812
Metoprolol Succinate66$712
Ezetimibe19$695
Potassium Chloride41$350
Atorvastatin Calcium51$348
ClopidogrelClopidogrel Bisulfate56$308
Losartan Potassium55$299
Pantoprazole Sodium31$241
Amiodarone Hcl39$236
Amlodipine Besylate38$171
Carvedilol23$170
Metoprolol Tartrate19$78
Furosemide54$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$204$18,08429 claims
Johnson & JohnsonXarelto$154$9,97016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.

Other family in Council Bluffs

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →